GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
Nasdaq listing is quite obviously more of an immediate focus given the favorable market conditions.
With today’s presentation having a larger emphasis on US investors and our two largest investors also coming from the US, you can see how these forums in addition to next weeks Proactive one2one webcast is aimed at increasing shareholder awareness and thus valuation. We might also get an RNS in the near term to further assist with the rerating. We have a serious bottleneck of news building.
When guardant health sees its market cap eclipse $15b dollars today following a broker target some 33% higher than today’s current price. We know that the likes of Abbot and Merck are having to act so as to preserve market share from the threat of an emerging company like $GH.
Like you have pointed out, at £117m market cap, given the $130b annual market potential and when comparing to its peers or other relevant companies that have been taken over for $2.5b+ over the last few years, the potential for a rerate is imminent in my view.
This may explain the late movement in the share price on Thursday, it’s very interesting to see the key advantages of Parsortix over cell search and that it’s several years ahead of its competition which is yet to enter human trials.
I found of particular interest cell sizes dependent on cancer type (breast, prostate), and the benefit of carrying out the study using a more suitable size cassette to allow for the larger CTC size.
It’s just another massive tick in the box, with a new enhanced Parsortix system to be revealed and and in vitro de novo applications taking an average of 215 days from application during 2018/19, things are getting very exciting.
Agl daily increases are going very much under the radar. So many strong performing stocks recently, especially in the resource/renewable/Bitcoin sectors causing the market to look elsewhere, oblivious to the potential here.
It will take a significant one day move for this to be the case and to initiate new investors to dig a little deeper into the sheer scale of opportunity ahead that will give this the rerating it deserves.
Looked more like a PI dumping to chase a new target with the proceeds. We still have good demand for stock
t.me/
joinchat/
GStEocPlw4FMDhYI
Might work - delete gaps
t.me/
joinchat/
GStEocPlw4FMDhYI
Might work - delete gaps
Also gaining significant traction on the telegram group with over 200 members and lots of good discussion.
Very excited for this year!
After 21 years of investing (started when I was 13) have I ever discovered a company with such potential upside.
I have always been very aware of AGL and watched the stock price ebb and flow and I now hope to have got involved at what appears to be the business end of proceedings.
I have considered share price behavior prior to FDA approval for companies such as Polx and Stx, looking at market cap compared to the size of the target market that they are to tackle in the event of approval ($2/4b). But when I compare the respective target market and competition against Agl’s $130b target market and its multiple routes/lines to revenue generation the mind boggles.
I only have to look to Agl’s peers and M&A within the industry to realize the true potential here, and for me I will now sit on my hands and watch this company turn into a multi-billion pound company. Not only am I expecting this to list on the Nasdaq but become a FTSE 100 company in time.
Between now and the 25th February, going into mid year I expect the Euphoria around the potential to reach new highs, with a bottleneck of news building on multiple fronts. 100/200p prior to approval given the time the company took to minimize risk going into approval, is by no means unrealistic. If it wasn’t for the relative small pool of investors this side of the pond, if this was listed on Nasdaq, I’m prettying sure the share price would already be many multiples of today’s price.
Happy new year.
All these 47p trades are buys, they are flooding in. Now only a matter of time before it goes on another leg up imo!
I believe it’s a possibility given the potential vulnerability of the project and share structure. Having said that it’s only a possibility and the company to date hasn’t communicated the project as if it’s a short term horizon to exit.
Valuation remains compelling regardless in the medium term.
Why?
When you look at Pre and it’s performance/market cap now exceeding £200m with less money in the bank and located in Angola. Although the material is different, the projected growth in demand is similar.
I think you can look to Pre share price as a similar precursor to what will happen to the share price here! At some point in the near future it will make a stride forward on no news but to its next technical point of 78.5p and even then it would have lower market cap than Pre. Pre increase 30% yesterday alone.
When you look at it’s peers, yes they are further down the development curve but equally the market cap is 7/8x that of BCN, it speaks volumes for how under the radar this stock is.
With the company confirming by way of a recent interview that it already has the funds in place for the construction of the mine. Q1 will reveal the America investors that will see this deposit close to their border as a strategic asset.
I have said on another board, that I don’t think it will be long before the company is subject to a hostile bid from Ganfeng as the structure of the current deal is 50/50. Interestingly Lithium America retained a 51/49 interest.
One of those is a one of my buys, not all of, if any were sells. You couldn’t even buy any for the last 15 minutes and could sell on the ask as many as you wanted.
I did find it strange that the Supreme Court had ruled in favor of BKY a week earlier than Fridays press release and yet the company didn’t find it as grounds for an RNS. Today we could also see that this news was secondary to the most important update which confirmed that the NSC I will be in place for as long as it takes to get NSC II. All of which is favorably staking in favor of BKY, with a depressed European Economy only adding further fuel to the fire for local job creation.
Very encouraging.
When looking at industry sentiment such as NCYT performance today it won’t take long for that to transfer here. We should be at 170+ levels imo as if you truly believe the company will deliver like I do, we are working from a very low historical (Covid related) base.
Big returns for those with patience imo!
It’s all their in the RNS,
- A highly scalable test device using ‘readily available components’ and routine manufacturing processes
Readily available components, nothing complicated here from BBI
- The performance of the test with clinical samples will now be evaluated as a precursor to a much larger clinical study with COVID-19 patients of known viral load to determine the clinical sensitivity of the test.
With AI confirming in his director interview that the clinical study has already been put in place, thus a date is likely along the project timeline.
With the UK government then hopeful of putting BAMS testing in place in December as per the head of the trials communicated on Twitter, we have plenty of newsflow to come on all fronts and impatient robinhood investors or bitter bystanders will watch it unfold.
I think the Nasdaq and this link indicates the true value and future potential scale of Avacta’s therapeutic division:
https://investingnews.com/daily/life-science-investing/biotech-investing/top-oncology-companies/
Given earlier comments from 2019 that implied that they may consider splitting the diagnostics and therapeutic divisions, it is one way of minimizing dilution by listing the therapeutic division on the Nasdaq. It will also serve the purpose of reducing Covid sentiment from the core business.
Imo, the underlying strength in the share price is indicative of the share price now representing very little value for the diagnostics business as the higher market cap and subsequent raise that minimized dilution by comparison to what would of been the case had the share price not of rerated.
Covid has presented a whole new dynamic to the business model as it aims to show that the therapy will be safe in man. This will then lead to significant upfront payments from future collaborators/partners compared to what it has received to date.
For me, Avacta remains a sitting duck to one of the cash rich big boys and a takeover cannot be ruled out in the future.
We all know that the biotech/Pharma sector has now moved into Vogue and will remain popular for some time to come.
Newsflow over the course of the next several weeks will take the market cap to a new level imo.
Avacta IP is of extreme value and is now very much in the sectors sights.
They want all my stock, the hole lot. The demand is huge!
Wow, the strength and underlying/unreported demand for this stock over the last few days has been incredible.
This has to be institutional investors at play!
Mow - hot money.
Not referring to investors.